ADMA Biologics, Inc. (ADMA)
NASDAQ: ADMA · Real-Time Price · USD
9.55
-0.03 (-0.31%)
Sep 4, 2026, 2:39 PM EDT - Market open
ADMA Biologics Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 2,139 | 4,341 | 4,054 | 1,021 | 857 | 276 | |
Market Cap Growth | -47.88% | 7.08% | 296.93% | 19.17% | 210.44% | 49.75% |
Enterprise Value | 2,207 | 4,363 | 4,079 | 1,100 | 975 | 343 |
Last Close Price | 9.58 | 18.24 | 17.15 | 4.52 | 3.88 | 1.41 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 13.65 | 29.55 | 20.51 | - | - | - |
Forward PE | 10.74 | 22.24 | 25.28 | 36.16 | - | - |
PS Ratio | 4.13 | 8.51 | 9.51 | 3.96 | 5.56 | 3.41 |
PB Ratio | 5.29 | 9.10 | 11.62 | 7.55 | 5.64 | 1.96 |
P/TBV Ratio | 5.23 | 9.18 | 11.75 | 7.79 | 5.81 | 2.03 |
P/FCF Ratio | 18.15 | 156.04 | 36.71 | 253.51 | - | - |
P/OCF Ratio | 15.47 | 86.14 | 34.16 | 116.07 | - | - |
PEG Ratio | 0.36 | 1.37 | 1.20 | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 4.26 | 8.55 | 9.56 | 4.26 | 6.33 | 4.24 |
EV/EBITDA Ratio | 9.73 | 21.86 | 27.74 | 35.88 | - | - |
EV/EBIT Ratio | 10.08 | 22.79 | 29.35 | 49.27 | - | - |
EV/FCF Ratio | 18.74 | 156.82 | 36.93 | 273.07 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.50 | 0.17 | 0.24 | 1.05 | 1.02 | 0.73 |
Debt / EBITDA Ratio | 0.90 | 0.40 | 0.55 | 4.28 | - | - |
Debt / FCF Ratio | 1.75 | 2.87 | 0.74 | 35.10 | - | - |
Net Debt / Equity Ratio | 0.17 | -0.02 | -0.06 | 0.67 | 0.45 | 0.37 |
Net Debt / EBITDA Ratio | 0.30 | -0.04 | -0.14 | 2.94 | -2.11 | -0.99 |
Net Debt / FCF Ratio | 0.58 | -0.28 | -0.19 | 22.35 | -0.92 | -0.41 |
Asset Turnover | 0.83 | 0.92 | 1.04 | 0.76 | 0.49 | 0.34 |
Inventory Turnover | 0.84 | 1.15 | 1.21 | 1.01 | 0.83 | 0.77 |
Quick Ratio | 3.62 | 3.54 | 2.76 | 1.58 | 2.60 | 2.62 |
Current Ratio | 6.97 | 6.71 | 5.97 | 5.16 | 6.89 | 6.87 |
Return on Equity (ROE) | 41.90% | 35.56% | 81.64% | -19.67% | -44.96% | -62.46% |
Return on Assets (ROA) | 21.78% | 21.50% | 21.24% | 4.12% | -7.88% | -14.87% |
Return on Invested Capital (ROIC) | 36.24% | 38.62% | 50.24% | 10.03% | -19.07% | -35.65% |
Return on Capital Employed (ROCE) | 35.60% | 34.50% | 32.10% | 8.00% | -12.70% | -23.40% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 7.99% | 3.38% | 4.88% | -2.77% | -7.69% | -25.95% |
FCF Yield | 5.51% | 0.64% | 2.72% | 0.39% | -8.57% | -45.59% |
Buyback Yield / Dilution | -1.15% | -5.07% | -4.07% | -13.19% | -41.77% | -62.03% |